Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.09
BASI's Cash to Debt is ranked lower than
92% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. BASI: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
BASI' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.09
Equity to Asset 0.40
BASI's Equity to Asset is ranked lower than
75% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. BASI: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
BASI' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.44 Max: 0.83
Current: 0.4
0.31
0.83
F-Score: 4
Z-Score: -0.24
M-Score: -3.26
WACC vs ROIC
2.64%
-12.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -9.63
BASI's Operating margin (%) is ranked lower than
58% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. BASI: -9.63 )
Ranked among companies with meaningful Operating margin (%) only.
BASI' s Operating margin (%) Range Over the Past 10 Years
Min: -20.16  Med: 2.56 Max: 6.7
Current: -9.63
-20.16
6.7
Net-margin (%) -9.40
BASI's Net-margin (%) is ranked lower than
56% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. BASI: -9.40 )
Ranked among companies with meaningful Net-margin (%) only.
BASI' s Net-margin (%) Range Over the Past 10 Years
Min: -22.39  Med: -3.96 Max: 6.95
Current: -9.4
-22.39
6.95
ROE (%) -18.42
BASI's ROE (%) is ranked lower than
56% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. BASI: -18.42 )
Ranked among companies with meaningful ROE (%) only.
BASI' s ROE (%) Range Over the Past 10 Years
Min: -55.71  Med: -9.73 Max: 18.44
Current: -18.42
-55.71
18.44
ROA (%) -8.24
BASI's ROA (%) is ranked lower than
52% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. BASI: -8.24 )
Ranked among companies with meaningful ROA (%) only.
BASI' s ROA (%) Range Over the Past 10 Years
Min: -21.3  Med: -3.97 Max: 7.42
Current: -8.24
-21.3
7.42
ROC (Joel Greenblatt) (%) -10.22
BASI's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. BASI: -10.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BASI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -28.7  Med: 2.3 Max: 15.35
Current: -10.22
-28.7
15.35
Revenue Growth (3Y)(%) -13.10
BASI's Revenue Growth (3Y)(%) is ranked lower than
77% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. BASI: -13.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BASI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -23.4  Med: -1.55 Max: 14.9
Current: -13.1
-23.4
14.9
» BASI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-12-17)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BASI Guru Trades in Q3 2015

Jim Simons 14,600 sh (+17.74%)
» More
Q4 2015

BASI Guru Trades in Q4 2015

Jim Simons 15,500 sh (+6.16%)
» More
Q1 2016

BASI Guru Trades in Q1 2016

Jim Simons 17,000 sh (+9.68%)
» More
Q2 2016

BASI Guru Trades in Q2 2016

Jim Simons 17,700 sh (+4.12%)
» More
» Details

Insider Trades

Latest Guru Trades with BASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCBB:RPBIF, NAS:TBIO, OTCPK:BTHCF, NAS:ROKA, OTCPK:LEDIF, OTCPK:MDIT, NAS:CBMX, NAS:ATOS, NAS:SGNL, OTCPK:OXIS, NAS:APPY, OTCPK:ETAH, OTCPK:DIGP, OTCPK:MTST, NAS:BIOC, NAS:CAPN, OTCPK:BMKDF, OTCPK:ABMC, NAS:IDXG, OTCPK:IMEXF » details
Traded in other countries:BS5.Germany,
Bioanalytical Systems Inc is a contract research organization providing drug discovery and development services and analytical instruments. Its customers and partners include pharmaceutical, biotechnology, academic and government organizations.

Bioanalytical Systems Inc is a corporation organized in Indiana in 1974. The Company is a contract research organization providing drug discovery and development services and analytical instruments. Its clients and partners include pharmaceutical, biotechnology, academic and government organizations. It supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The Companys principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the largest global pharmaceutical companies. The drug discovery and development process is heavily regulated by the FDA and its Center for Drug Evaluation and Research. It operates in two business segments contract research services and research products, both of which address the bioanalytical, preclinical, and clinical research needs of drug developers. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing. The services provided by its contract research services segment include Product Characterization, Method Development and Validation, Bioanalytical Testing, Stability Testing, In Vivo Pharmacology, and Preclinical and Pathology Services. The products business targets life science research and designs, develops, manufactures and markets Analytical Products, In vivo Sampling Products, Vetronics Products. It promotes its services through concentrated business development efforts, scientist-to-scientist communications and centralized corporate marketing programs. The Company competes with in-house research, development, quality control and other support service departments of pharmaceutical and biotechnology companies. Its competitors include Covance, Inc., Pharmaceutical Product Development, Inc., Charles River Laboratories, Inc., Quintiles Transnational Holdings, Inc. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its data and products.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 34.85
BASI's Price/Owner Earnings (ttm) is ranked lower than
59% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.42 vs. BASI: 34.85 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BASI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.79  Med: 12.4 Max: 170.59
Current: 34.85
3.79
170.59
P/B 1.13
BASI's P/B is ranked higher than
89% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. BASI: 1.13 )
Ranked among companies with meaningful P/B only.
BASI' s P/B Range Over the Past 10 Years
Min: 0.23  Med: 1.36 Max: 3.22
Current: 1.13
0.23
3.22
P/S 0.47
BASI's P/S is ranked higher than
93% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. BASI: 0.47 )
Ranked among companies with meaningful P/S only.
BASI' s P/S Range Over the Past 10 Years
Min: 0.1  Med: 0.5 Max: 1.14
Current: 0.47
0.1
1.14
POCF 8.27
BASI's POCF is ranked higher than
82% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. BASI: 8.27 )
Ranked among companies with meaningful POCF only.
BASI' s POCF Range Over the Past 10 Years
Min: 1.24  Med: 7.93 Max: 41.72
Current: 8.27
1.24
41.72
Current Ratio 0.46
BASI's Current Ratio is ranked lower than
92% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. BASI: 0.46 )
Ranked among companies with meaningful Current Ratio only.
BASI' s Current Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.11 Max: 3.95
Current: 0.46
0.35
3.95
Quick Ratio 0.35
BASI's Quick Ratio is ranked lower than
92% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BASI: 0.35 )
Ranked among companies with meaningful Quick Ratio only.
BASI' s Quick Ratio Range Over the Past 10 Years
Min: 0.24  Med: 0.81 Max: 3.05
Current: 0.35
0.24
3.05
Days Inventory 34.63
BASI's Days Inventory is ranked higher than
72% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. BASI: 34.63 )
Ranked among companies with meaningful Days Inventory only.
BASI' s Days Inventory Range Over the Past 10 Years
Min: 22.9  Med: 29.38 Max: 36.89
Current: 34.63
22.9
36.89
Days Sales Outstanding 44.98
BASI's Days Sales Outstanding is ranked higher than
72% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. BASI: 44.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
BASI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.96  Med: 53.3 Max: 81.92
Current: 44.98
37.96
81.92
Days Payable 93.03
BASI's Days Payable is ranked higher than
66% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. BASI: 93.03 )
Ranked among companies with meaningful Days Payable only.
BASI' s Days Payable Range Over the Past 10 Years
Min: 18.44  Med: 31.55 Max: 93.03
Current: 93.03
18.44
93.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
BASI's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. BASI: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BASI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: -1.95 Max: -0.1
Current: -2
-16.1
-0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.28
BASI's Price/Tangible Book is ranked higher than
92% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.65 vs. BASI: 1.28 )
Ranked among companies with meaningful Price/Tangible Book only.
BASI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.33  Med: 1.5 Max: 3.33
Current: 1.28
0.33
3.33
Price/Projected FCF 0.87
BASI's Price/Projected FCF is ranked higher than
93% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. BASI: 0.87 )
Ranked among companies with meaningful Price/Projected FCF only.
BASI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.33  Med: 1.04 Max: 63
Current: 0.87
0.33
63
Price/Median PS Value 0.93
BASI's Price/Median PS Value is ranked higher than
63% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. BASI: 0.93 )
Ranked among companies with meaningful Price/Median PS Value only.
BASI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.26 Max: 3.93
Current: 0.93
0.26
3.93
Earnings Yield (Greenblatt) (%) -10.30
BASI's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. BASI: -10.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BASI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.3  Med: 3.7 Max: 19.7
Current: -10.3
-10.3
19.7
Forward Rate of Return (Yacktman) (%) -7.84
BASI's Forward Rate of Return (Yacktman) (%) is ranked lower than
86% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.43 vs. BASI: -7.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BASI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.6  Med: 6.6 Max: 34.5
Current: -7.84
-11.6
34.5

More Statistics

Revenue (TTM) (Mil) $20.26
EPS (TTM) $ -0.23
Beta-0.07
Short Percentage of Float0.63%
52-Week Range $0.90 - 1.87
Shares Outstanding (Mil)8.11
» More Articles for BASI

Headlines

Articles On GuruFocus.com
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 09 2011 
Bioanalytical Systems Inc. Reports Operating Results (10-Q/A) May 20 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 17 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 16 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-K/A) Feb 10 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Aug 12 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 18 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 23 2009 

More From Other Websites
Bioanalytical (BASI) Launches Sampling System, Stock Down Aug 26 2016
BASi Launches Embrace Automation Grant Program with Culex NxT™ Automated Blood Sampling System Aug 25 2016
BASi Launches Embrace Automation Grant Program with Culex NxT™ Automated Blood Sampling System Aug 25 2016
BIOANALYTICAL SYSTEMS INC Financials Aug 23 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 10-Q, Quarterly Report Aug 15 2016
Bioanalytical Systems, Inc. :BASI-US: Earnings Analysis: Q3, 2016 By the Numbers : August 15, 2016 Aug 15 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2016
BASi Reports Third Quarter Results Aug 11 2016
Q3 2016 Bioanalytical Systems Inc Earnings Release - Before Market Open Aug 11 2016
Bioanalytical Systems to Release Third Quarter Fiscal 2016 Results on Thursday, August 11, 2016;... Aug 05 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Regulation FD Disclosure Aug 04 2016
Bioanalytical Systems to Release Third Quarter Fiscal 2016 Results on Thursday, August 11, 2016;... Aug 03 2016
BASi Expands Electrochemical Offerings by Partnering with PalmSens BV Jul 27 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Jul 22 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 06 2016
Edited Transcript of BASI earnings conference call or presentation 12-May-16 3:00pm GMT May 18 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 10-Q, Quarterly Report May 16 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... May 13 2016
Bioanalytical Systems, Inc. :BASI-US: Earnings Analysis: Q2, 2016 By the Numbers May 13 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)